



Alveolar Epithelial Type 2 Cell Dysfunction in Idiopathic Pulmonary Fibrosis

Weiwei Zhu¹ · Chunting Tan² · Jie Zhang¹

Received: 9 August 2022 / Accepted: 11 September 2022 / Published online: 22 September 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible pulmonary interstitial disease that seriously affects the patient's quality of life and lifespan. The pathogenesis of IPF has not been clarified, and its treatment is limited to pirfenidone and nintedanib, which only delays the decline of lung function. Alveolar epithelial type 2 (AT2) cells are indispensable in the regeneration and lung surfactant secretion of alveolar epithelial cells. Studies have shown that AT2 cell dysfunction initiates the occurrence and progression of IPF. This review expounds on the AT2 cell dysfunction in IPF, involving senescence, apoptosis, endoplasmic reticulum stress, mitochondrial damage, metabolic reprogramming, and the transitional state of AT2 cells. This article also briefly summarizes potential treatments targeting AT2 cell dysfunction.

Keywords Pulmonary fibrosis · Alveolar epithelial type 2 cell dysfunction · Metabolic reprogramming · Transitional state

Introduction

Idiopathic pulmonary fibrosis (IPF) is the most common and fatal idiopathic interstitial pneumonia. The median survival time from diagnosis is 2–4 years [1]. Because of the unclear pathogenesis, limited treatment drugs are available. Pirfenidone and nintedanib, antifibrotic medicines approved by FDA, were shown to slow down the forced vital capacity (FVC) reduction rate, but they do not improve the survival rate of patients [2]. Better understanding of the pathogenesis of IPF will lead to the development of new treatment strategies and medications.

In Europe and North America, the incidence of IPF is between 2.8 and 19 cases per 100,000 people per year, and the prevalence of IPF increases with age. Disease onset

is usually at 60 years old, and the peak of disease occurs between 60 and 70 years of age [3]. IPF is an aging-related disease, and AT2 cell aging participates in the occurrence of IPF [4]. AT2 cells in IPF patients show mitochondrial stress, endoplasmic reticulum stress, and gene mutation. Recent studies have also identified metabolic reprogramming and paracrine changes in AT2 cells of IPF patients [5, 6]. Compared with AT2 cells directly transforming into mesenchymal cells, the transformation of fibroblasts into muscle fibroblasts caused by the paracrine signals of AT2 cells is more important to IPF [6]. This article summarizes the role of AT2 cells in IPF from two aspects: the dysfunction of AT2 cells in IPF and the change of signaling between AT2 cells and surrounding cells (mesenchymal cells, macrophages) during IPF (Table 1).

AT2 Cell Senescence or Apoptosis is Dominant in IPF

Mutations in telomerase and telomere genes can lead to abnormal telomere shortening. Clinically, this molecular abnormality is manifested as telomere syndromes characterized by aging. IPF is the most common clinical manifestation of human telomere syndrome [31]. In IPF patients, AT2 cells have the shortest telomere length compared with club cells and myofibroblasts; AT2 cells also show the most

✉ Chunting Tan
chuntingtan@ccmu.edu.cn

✉ Jie Zhang
zhangj_tt@163.com

¹ Department of Respiratory Medicine, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing 100070, People's Republic of China

² Department of Respiratory Medicine, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong An Road, Xicheng District, Beijing 100050, People's Republic of China

Table 1 Signaling pathways of AT2 cell dysfunction in IPF

Pathways	Objects	References
Senescence and apoptosis		
Trf2/DNA damage at telomeres/p53 pathway	Mice, primary murine AT2 cells	[7]
Bmi-1/TIME signaling/SASP	human pulmonary samples, mice, primary murine AT2 cells and fibroblasts	[8]
Sin3a/p53-p21 axis/AT2 senescence	IPF patients, mice, primary murine epithelial cells	[9]
TSPAN1/p-IκBα/NF-κB/AT2 cell apoptosis	IPF patients, mice, A549 cell line, primary murine AT2 cells	[10]
PAI-1/p53 Phosphorylation	mice, primary murine AT2 cells and fibroblasts	[11]
Endoplasmic reticulum stress and mitochondrial damage		
Grp78/ER stress/AT2 cell aging phenotype	Mice	[12]
FKBP13/UPR/ER stress	IPF patients, mice	[13]
ER stress/ATF3/PINK1/Mitophagy	Mice, A549 cell line, primary human AECIIs	[14]
ER stress/UPR/PACS2-TRPV1/ER-Mito tethering	IPF patients, MLE12 cell line, MEL188 cell line,	[15]
mitoROS/NAD ⁺ /PARP1/SIRT1/mitophagy	Mice, MLE12 cell line	[16]
SIRT3/OGG1/mitophagy/mtDNA	Mice, early-passage human lung fibroblasts	[17]
Klotho/AKT signaling/mtDNA damage	Mice, primary murine AT2 cells, A549, MLE12, and RLE-6TN cell lines	[18]
Transitional state and paracrine		
RhoGTPase Cdc42 /AT2 intermediate cell/ AT2 differentiation	IPF patients, mice, primary murine AT2 cells and stromal cells	[19]
PATS/AT2 differentiation	Mice, alveolar organoid	[20]
Nedd4-2/TGFβ- p-SMAD2/ p-SMAD3	IPF patients, mice, primary murine AT2 cells	[21]
MIR100HG/miR-29a-3p/Tab1/TIMP-1/MMP-1	Mice, MLE12 cell line	[22, 23]
EGFR-RAS-ERK/ZEB1/tPA/TGFβ-1	IPF patients, primary human parenchymal lung fibroblast, primary human AT2 cells	[24]
PDGFA / PDGFRA/AT2 differentiation	Mice, human organoids, Mouse lung organoids	[25]
SIX1/MIF/ Proliferation of fibroblasts	IPF patients, primary human AT2 cells and fibroblasts, mice, primary murine AT2 cells, MLE12 cell line	[26]
Inflammation		
Lrrk2/CCL2-CCR2 axis	Mice	[27]
MCP-1/CCR2/TGF-β axis	Mice, primary murine macrophages and AT2 cells	[28]
Shh/Gli1-OPN-JAK2/STAT3	Mice, bone marrow-derived macrophages, MLE12 cell line	[29]
MCU/Cpt1a/Bcl-2/TGFβ-1	Mice, human THP-1 monocytes, Mouse MH-S alveolar macrophage cells	[30]

serious DNA damage, which is mainly caused by telomere shortening [32]. AT2 cells in mice with telomeric repeat-binding factor 2 (*Trf2*) gene knockout exhibit decreased proliferation and differentiation ability, but apoptosis was not increased, suggesting that telomere damage in AT2 cells preferentially initiates the cell aging process and damages cell renewal and differentiation ability. AT2 cells with *Trf2* gene deletion show upregulated *p53* expression through the paracrine pathway, induce mesenchymal cell apoptosis, and hinder normal lung development in mice [7]. *Bmi-1* deficiency leads to the accumulation of ROS and cytoplasmic p16, which induces AT2 cell senescence and senescence-associated phenotype (SASP) via the TGF-β1/IL-11/MEK-ERK (TIME) pathway [8]. *Sin3a* gene deletion also induces cell cycle arrest and aging of AT2 cells by activating the p53-p21 axis, which promotes the occurrence of pulmonary fibrosis [9].

AT2 cell apoptosis in IPF is also a research hotspot. Studies have found that specific depletion of AT2 cells induces pulmonary fibrosis in mice. At present, there are three models of AT2 cell-specific injury: the murine surfactant protein C (SPC) promoter and the diphtheria toxin receptor gene (SPC-DTR) mouse model induced by diphtheria toxin; the tamoxifen-inducible SPC-CreER mouse model, which drives the expression of diphtheria toxin A in AT2 cells; and the ganciclovir-induced transgenic mouse model, in which the SPC promoter drives expression of mutant SR39TK herpes simplex virus-1 thymidine kinase in AT2 cells [33–35]. TSPAN1 is a member of the tetraspanins family and is downregulated in lung tissue of patients with IPF and bleomycin-induced pulmonary fibrosis mice. TSPAN1 inhibited AT2 cell apoptosis by inhibiting p-IκBα, which attenuated nuclear NF-κB translocation and activation [10]. The apoptotic sensitivity of AT2 cells increases, while the

apoptotic sensitivity of fibroblasts decreases in the lung of aged mice, which is related to the fact that plasma activator inhibitor 1 (PAI-1) can positively or negatively regulate the phosphorylation and expression of *p53* according to cell type [11].

Endoplasmic Reticulum Stress of AT2 Cells Promotes IPF

GRP78 is one of the important modifiers of controlling protein quality by activating the unfolded protein response (UPR) in the endoplasmic reticulum. Mice with *Grp78* gene knockout develop spontaneous pulmonary fibrosis, and AT2 cells with *Grp78* gene knockout are characterized by endoplasmic reticulum stress, apoptosis, senescence, and impaired stem cell ability [12]. Endoplasmic reticulum stress inhibitors decrease the expression of markers of cell aging, apoptosis, and mesenchymal cells [12]. The UPR maintains protein homeostasis by enhancing the ability of the ER to refold proteins and reducing the translation of abnormal proteins [36]. *Fkbp13* (13-kD FK506-binding protein) level positively correlated with the UPR marker GRP78

and total XBP1. *Fkbp13* knockout mice were more sensitive to bleomycin and showed increased early inflammatory cells (macrophages, neutrophils, lymphocytes) and proinflammatory factors (IL-6, TGF β -1) [13]. In mice harboring L188Q mutation in *SFTPC*, which encodes SPC, ER stress is induced but the mice do not show spontaneous fibrosis; upon exposure to bleomycin, much greater lung fibrosis was observed compared with fibrosis in WT mice [37]. In the *SFTPC* BRICHOS mouse model with C121G mutation in *SFTPC*, mice show high levels of ER stress in AT2 cells and spontaneous pulmonary fibrosis [38]. These models indicate ER stress as a key driver of lung fibrosis.

Excessive ER stress damages the signal network with mitochondria and causes mitochondrial dysfunction (Fig. 1). ER stress of AT2 cells impairs mitophagy by activating transcription factor 3 (ATF3) and repressing transcription of the PTEN-induced putative kinase 1 (PINK1) gene [14]. Mitophagy dysfunction promotes AT2 cell aging and IPF [39]. When UPR cannot be compensated due to persistent ER stress, ER-mitochondrial tethering will decrease, and the expression of transient receptor potential cation channel subfamily V member 1 (TRPV1) and phosphofulic acid cluster sorting protein 2 (PACS2) are downregulated. The deletion




Fig. 1 The mechanism of AT2 cell senescence and apoptosis. The solid line indicates promotion and the dotted line indicates inhibition

of *Pacs2* has been proven to induce the cleavage of BAP31 to lead to mitochondrial-dependent apoptosis. In vitro and ex vivo experiments showed that ER-mitochondrial tethering induced by ER stress was related to the PACS2-TRPV1 axis [40]. The TRPV1-modulating drug capsaicin (CPS) inhibited the degradation of TRPV1, increased the level of PACS2 protein, and reduced the apoptosis of alveolar epithelial cells and collagen expression [15].

Mitochondrial Damage and Metabolism Reprogramming of AT2 Cells Participate in IPF

Mitochondrial DNA (mtDNA) and mitophagy damage are critical factors in the process of IPF (Fig. 1). Cigarette smoke (CS) may cause mitochondrial reactive oxygen species (mitoROS), mitoROS-induced DNA damage activates poly ADP-ribose polymerase (PARP1), which competitively depletes nicotinamide adenine dinucleotide (NAD⁺) with SIRT1. Suppressed SIRT1 leads to a lack of regulation of mitophagy, resulting in DNA damage and AT2 cell senescence. Mitophagy damage in turn leads to mitoROS, resulting in a positive feedback between mitophagy and SIRT1 [16]. SIRT1 activator and mitoROS scavenger can inhibit CS-induced AT2 cell senescence and pulmonary fibrosis [16].

SIRT3 also inhibits ROS-induced damage to mitochondrial DNA by preventing acetylation of 8-oxoguanine DNA glycosylase (OGG1). Deacetylation of OGG1 is essential for maintaining DNA integrity by preventing mitophagy from being damaged [17]. OGG1 can prevent mitophagy dysfunction caused by PINK1 deficiency to avoid AT2 cell aging and alleviate IPF [39]. SIRT7 participates in the mitochondrial UPR, which is important for AT2 cell homeostasis [41]. *Klotho* is an anti-aging gene and *Klotho* indirectly prevents lung fibrosis through lessening mtDNA damage and apoptosis of AT2 cells [18, 42, 43]. *Klotho* promotes FGFR1 binding to FGF23 and activates AKT signaling to prevent apoptosis of AT2 cells caused by mtDNA damage [44, 45].

Studies have shown that MLE12 exhibits mitochondrial respiratory inhibition after bleomycin induction for 3 h, specifically manifested as the decline in oxidative phosphorylation. Mitochondrial respiratory inhibition is accompanied by DNA damage (γ -H2AX is upregulated). The glycolysis of cells induced by bleomycin is also inhibited, which involves the significant decrease of the expression of glucose uptake and transport 1 (GLUT1), the decrease of the exchange rate of intermediate products of the tricarboxylic acid cycle, and the decrease of extracellular acidification rate (ECAR) [46]. Another study showed that iAEC2s with SFTPC^{I73T} gene mutation exhibit damaged oxidative phosphorylation and higher glycolysis [5].

In addition, inhibiting glutamine metabolism can inhibit the proliferation and differentiation of AT2 cells. The specific mechanism may be that the inhibition of glutamine metabolism reduces α -KG production, which is the most important intermediate product in the tricarboxylic acid cycle. The impaired TCA cycle and limited ATP are not conducive to the regeneration of damaged cells [47]. Glutamine can maintain various intermediates of the TCA cycle and pentose phosphate pathway, glycolytic intermediates, and almost all amino acids. Bleomycin-damaged MLE12 can restore cell mitochondrial respiration and ECAR after supplementing glutamine [46]. Glutamine can also reduce the cytotoxicity of bleomycin, because glutamine and α -KG play important roles in nucleotide synthesis and DNA repair, respectively [48, 49].

Transitional State of AT2 Cells in IPF

A previous study identified the presence of aberrant basaloid cells, which is a previously unidentified epithelial cell population, that coexpress basal epithelial markers, mesenchymal markers, aging markers, developmental transcription factors, and known IPF markers [50]. AT2 cells in the IPF lung can also differentiate into KRT5⁺ basal cells in response to fibrotic signaling. TGF β -1 and anti-bone morphogenic protein (anti-BMP) promote this transdifferentiation [51]. In models of progressive lung fibrosis and human IPF patients, AT2 cells can differentiate into Krt8⁺ alveolar differentiation intermediate (ADI), which can reprogram into AT1 cells [52]. RhoGTPase Cdc42 depletion leads to an accumulation of cells in the AT2 intermediate cell state, which prevents AT2 cells from differentiating into AT1 cells. This impaired regenerative ability causes AT2 cells to be exposed to persistently elevated mechanical tension, activates the TGF- β signal in AT2 cells, and promotes periphery-to-center progression of lung fibrosis [19]. Another study showed that there was accumulation of pre-alveolar type-1 transitional cell state (PATS), an intermediate cell state during the differentiation of AT2 cells into AT1 cells, in the pulmonary fibrosis area of IPF patients. PATS cells in human lungs exhibit enrichment of genes associated with cellular senescence, TP53 signaling, and TGF- β -regulated genes. Moreover, PATS cells are vulnerable to DNA damage during the process of differentiation from AT2 cells to AT1 cells (Fig. 2). Long-term aging and stress regulatory signals in transitional cells will promote the occurrence of fibrosis [20].

AT2 cells without Nedd4-2 can also lead to epithelial remodeling of the peripheral airway, mainly manifested as decreased club cells, increased ciliated cells and goblet cells in local and terminal airways. The expression of MUC5B in proximal and distal airways is also increased. Deletion of Nedd4-2 in AT2 cells increases the activity of ENaC,




Fig. 2 The mechanism of transitional state and paracrine signals of AT2 cells. The solid line indicates promotion and the dotted line indicates inhibition

which leads to the consumption of airway surface fluid and decreases mucociliary clearance [21]. The lncRNA mir-100-let-7a-2-mir-125b-1 cluster host gene (MIR100HG) modulates TGF- β -induced fibrotic changes in AT2 cells. It can increase the expression of TGF- β -activated kinase 1/ MAP3K7 binding protein 1 (Tab1) by inhibiting microRNA-29a-3p (mir-29a-3p), promote the production of TIMP-1, and inhibit the degradation of collagen by MMP-1 [22, 23]. Mir-29 can also activate the Wnt/ β -catenin pathway to promote TGF- β -induced extracellular matrix synthesis [53].

Paracrine Signals in AT2 Cells Contribute to IPF

Some studies have pointed out that only a small part of fibroblasts in fibrotic lesions come from AT2 cells [6]. Compared with the direct transformation of AT2 cells into

mesenchymal cells, the transformation from fibroblasts to myofibroblasts caused by the imbalance of paracrine signals is more important to EMT (Fig. 2). EGFR-RAS-ERK signaling in AT2 cells upregulates transcription regulator zinc finger E-box-binding homeobox 1 (ZEB1) and promotes AT2 cells to secrete tissue plasminogen activator (tPA), which can enhance TGF- β -induced myofibroblast differentiation [24]. AT2 cells can secrete TGF- β 2 after injury, which highlights the role of paracrine signals between AT2 cells and fibroblasts in mediating EMT [24]. Fibroblasts activated by TGF- β can secrete secreted protein acidic and rich in cysteine (SPARC), which can activate EGFR-RAS signal transduction in AT2 cells. Thus, the bidirectional epithelial–mesenchymal crosstalk promotes the progression of fibrosis [54]. Studies have shown that AT2 cells in IPF patients have not completely lost the ability to differentiate into AT1 cells. PDGFA ligands activate beneficial feedback of the epithelial–mesenchymal crosstalk by promoting

PDGFR α + fibroblast differentiation into beneficial PDGFRA+ matrix fibroblasts. PDGFRA+ matrix fibroblasts promote the differentiation of AT2 cells into AT1 cells [25]. A specific balance between the activation of the PDGFA ligand and inhibition of the PDGF-B ligand may enhance alveolar repair [25]. These findings suggest that the changes in signal connections between AT2 cells themselves or between AT2 cells and mesenchymal cells are involved in the occurrence of pulmonary fibrosis.

The developmental transcription factor *Sine oculis homeobox homolog 1* (*SIX1*) plays an important role in lung development [55]. The mRNA and protein levels of *Six1* and its transcriptional coactivators (*EYA1* and *EYA2*) were increased in AT2 cells of bleomycin-induced pulmonary fibrosis model mice and telomere dysfunction pulmonary fibrosis model mice [26, 56]. The mechanism of *Six1* in promoting the progression of pulmonary fibrosis may be related to the downstream macrophage migration inhibitory factor (*MIF*). *SIX1* directly binds to the 5'-TCAGG-3' consensus sequence of the *MIF* promoter, and *MIF* then promotes the proliferation of fibroblasts and the expression of α -SMA and *COL1A1* [26]. The treatment of pulmonary fibrosis targeting *MIF*, mainly in the form of anti-*MIF* antibody therapy and *MIF* antagonist, is still under study [57, 58].

Inflammation activated by AT2 cells aggravates IPF

iACE2s with *SFTPC*^{L73T} mutation activates the NF- κ B pathway and promote the secretion of inflammatory mediators (*GM-CSF*, *CXCL5*, and *MMP-1*) [5]. Activated WNT/ β -catenin signal in AT2 cells also induces downstream IL-1 β and IL-6, which activates TGF- β or STAT3 signal transduction, respectively [59]. Macrophage colony-stimulating factor (*M-CSF*) stimulates monocyte macrophages to produce CC chemokine ligand 2 (*CCL2*), which is involved in the occurrence of IPF [60]. The number of macrophages and neutrophils in alveolar lavage fluid and the secretion of IL-6 and monocyte chemoattractant protein 1 (*MCP-1*) are increased in pulmonary fibrosis mice induced by *GRP78* knockout [12].

The interaction between AT2 cells and immune cells such as pulmonary macrophages is also involved in pulmonary fibrosis. *Lrrk2* deletion can not only damage autophagy through ERK and JNK signaling pathways of AT2 cells, but also leads to activation of the *CCL2/CCR2* axis and recruitment of monocyte-derived macrophages [27]. Fibrosis induced by the *MCP-1/CCR2/TGF- β* axis was also present between injured AT2 cells and macrophages [28]. AT2 cells can also secrete Sonic hedgehog (*Shh*), initiate the *Shh/Gli* signal cascade, induce macrophages to secrete osteopontin, activate the *JAK2/STAT3* pathway, mediate M2 polarization

of macrophages, and promote pulmonary fibrosis [29]. Apoptosis resistance of pulmonary macrophages promotes the occurrence of pulmonary fibrosis. The mitochondrial calcium uniporter induces metabolic reprogramming to fatty acid β -oxidation and promotes the binding of carnitine palmitoyltransferase 1a (*CPT1A*) in mitochondria to the BH3 domain of mitochondrial B-cell lymphoma-2 (*Bcl-2*), decreases the proapoptotic proteins (*Puma* and *Noxa*), and inhibits the apoptosis of pulmonary macrophages. The interaction between *CPT1A* and *Bcl-2* increases TGF- β 1 in pulmonary macrophages, reduces antifibrosis protein (*TNF- α*), and promotes pulmonary fibrosis [30].

Potential Therapy Targeting AT2 Cells

Senescence and Regeneration

Dasatinib plus quercetin (*DQ*) can reduce aging markers in lung tissue of *Sin3a*-deficient mice and alleviate pulmonary fibrosis [9]. The clinical trial of *DQ* in the treatment of IPF shows that this drug can improve the physical function of patients [61]. Nicotinamide phosphoribosyltransferase (*NAMPT*) is the rate-limiting enzyme in the production of NAD⁺, and abnormal metabolism of *NAMPT* occurs in some aging-related diseases [62]. Research has found that *MSCs* inhibit AT2 cell aging by inhibiting lysosome-mediated degradation of *NAMPT* [63]. Human clinical trials have shown that a high-dose of allogeneic *MSCs* can delay the progress of IPF patients [64]. Recent studies propose that serum-free cultured *MSCs* (*SF-MSCs*) are easier to implant into mouse lungs after intravenous administration than serum cultured *MSCs* (*S-MSCs*). The antifibrosis effect of *SF-MSCs* is more pronounced compared with *S-MSCs* [65]. Lung niche mesenchymal cells promote the repair and regeneration of AT2 cells by secreting growth hormones, *Wnt5A* and chemokines. *Ghr*-enriched EVs promote the expression of *Ghr* in AT2 cells and the regeneration of AT2 cells [66].

ER Stress

Tauroursodeoxycholic acid (*TUDCA*) reduces ER stress markers (*GRP94* and *CHOP*) as well as mesenchymal markers [12]. *TUDCA* inhibits *BLM*-induced *CHOP* mRNA expression in a dose-dependent manner and presents protective effects against *BLM*-induced pulmonary fibrosis in mice [67]. Calcium and calmodulin-dependent kinase II (*CaMKII*) inhibition blocks ER stress and apoptosis induced by bleomycin in *MLE12* cells. A transgenic mouse model of *CaMKII* inhibition in type II pneumocytes exhibited a lower degree of pulmonary fibrosis than *WT* mice [68].

Mitochondrial Damage

MitoROS is involved in CS-induced senescence of AT2 cells. Mitochondria-targeted antioxidant mitoquinone (MitoQ) protects mice from CS-induced pulmonary fibrosis. SIRT1 activator and supplementation of NAD with its precursors can restore SIRT1 activity, prevent AT2 cell senescence, and inhibit CS-induced pulmonary fibrosis [16]. Thyroid hormone restores mitochondrial respiration in bleomycin-induced AT2 cells and limits the severity of pulmonary fibrosis in mice [69].

Conclusion and Future Insights

The pathogenesis of IPF mainly involves cell aging and apoptosis, mitochondria and endoplasmic reticulum dysfunction, abnormality of AT2 cell transitional state, paracrine signals in AT2 cells and inflammatory response. Mitochondria and endoplasmic reticulum oxidative stress, which can damage mitochondrial DNA, mitochondrial autophagy and the UPR, promote AT2 cell aging and apoptosis. The transformation of fibroblasts into myofibroblasts through the paracrine pathway of AT2 cells and AT2 cell transitional state also participate in IPF. The study on the pathogenesis of IPF should not be limited to AT2 cells themselves, and the paracrine effect on surrounding cells should also be studied. More potential therapies targeting AT2 cells including DQ, TUDCA, MitoQ, and Ghr-enriched EVs need to be further explored.

Author Contributions WZ conceived, wrote, and edited the manuscript. CT and JZ conceived and edited the manuscript. All authors read and approved the final manuscript.

Funding This work was supported by the National Natural Science Foundation of China (Grant No. 82000065), Beijing Key Clinical Specialty Construction Project (2020–2022).

Declarations

Competing Interests The authors have no relevant financial or non-financial interests to disclose.

Ethical Approval Not applicable.

Consent to Participate Not applicable.

Consent to Publish Not applicable.

References

- Lederer DJ, Martinez FJ (2018) Idiopathic pulmonary fibrosis. *N Engl J Med* 379(8):797–798. <https://doi.org/10.1056/NEJMc1807508>
- Raghu G, Rochwerf B, Zhang Y, Garcia CA, Azuma A, Behr J et al (2015) An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. *Am J Respir Crit Care Med* 192(2):3–19
- Olson AL, Gifford AH, Inase N, Fernandez PER, Suda T (2018) The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. *Eur Respir Rev* 27(150):180077
- Parimon T, Yao C, Stripp BR, Noble PW, Chen P (2020) Alveolar epithelial type II cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis. *Int J Mol Sci* 21(7):2269
- Alysandratos K-D, Russo SJ, Petcherski A, Taddeo EP, Acin-Perez R, Villacorta-Martin C et al (2021) Patient-specific iPSCs carrying an SFTPC mutation reveal the intrinsic alveolar epithelial dysfunction at the inception of interstitial lung disease. *Cell Rep*. <https://doi.org/10.1016/j.celrep.2021.109636>
- Tan W, Wang Y, Chen Y, Chen C (2021) Cell tracing reveals the transdifferentiation fate of mouse lung epithelial cells during pulmonary fibrosis in vivo. *Exp Ther Med*. <https://doi.org/10.3892/etm.2021.10622>
- Alder JK, Barkauskas CE, Limjunyawong N, Stanley SE, Kembou F, Tudor RM et al (2015) Telomere dysfunction causes alveolar stem cell failure. *Proc Natl Acad Sci USA* 112(16):5099–5104. <https://doi.org/10.1073/pnas.1504780112>
- Chen H, Chen H, Liang J, Gu X, Zhou J, Xie C et al (2020) TGF-beta1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency. *Exp Mol Med* 52(1):130–151
- Yao C, Guan X, Carraro G, Parimon T, Liu X, Huang G et al (2021) Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis. *Am J Respir Crit Care Med* 203(6):707–717. <https://doi.org/10.1164/rccm.202004-1274OC>
- Yang L, Wang Y, Pan Z, Gao S, Zou B, Lin Z et al (2018) Tetraspanin 1 inhibits TNF α -induced apoptosis via NF- κ B signaling pathway in alveolar epithelial cells. *Inflamm Res* 67(11–12):951–964. <https://doi.org/10.1007/s00011-018-1189-9>
- Jiang C, Liu G, Cai L, Deshane J, Antony V, Thannickal VJ et al (2021) Divergent regulation of alveolar type 2 cell and fibroblast apoptosis by plasminogen activator inhibitor 1 in lung fibrosis. *Am J Pathol* 191(7):1227–1239. <https://doi.org/10.1016/j.ajpath.2021.04.003>
- Borok Z, Horie M, Flodby P, Wang H, Liu Y, Ganesh S et al (2020) Grp78 loss in epithelial progenitors reveals an age-linked role for endoplasmic reticulum stress in pulmonary fibrosis. *Am J Respir Crit Care Med* 201(2):198–211
- Tat V, Ayaub EA, Ayoub A, Vierhout M, Naiel S, Padwal MK et al (2021) FK506-binding protein 13 expression is upregulated in interstitial lung disease and correlated with clinical severity. A potentially protective role. *Am J Respir Cell Mol Biol* 64(2):235–246. <https://doi.org/10.1165/rcmb.2020-0121OC>
- Bueno M, Brands J, Voltz L, Fiedler K, Mays B et al (2018) ATF3 represses PINK1 gene transcription in lung epithelial cells to control mitochondrial homeostasis. *Aging Cell* 17(2):e12720
- Knoell J, Chillappagari S, Knudsen L, Korfei M, Dartsch R, Jonigk D et al (2022) PACS2-TRPV1 axis is required for ER-mitochondrial tethering during ER stress and lung fibrosis. *Cell Mol Life Sci* 79(3):151. <https://doi.org/10.1007/s00018-022-04189-2>
- Zhang Y, Huang W, Zheng Z, Wang W, Yuan Y, Hong Q et al (2021) Cigarette smoke-inactivated SIRT1 promotes autophagy-dependent senescence of alveolar epithelial type 2 cells to induce pulmonary fibrosis. *Free Radic Biol Med* 166:116–127
- Bindu S, Pillai VB, Kanwal A, Samant S, Mutlu GM, Verdin E et al (2017) SIRT3 blocks myofibroblast differentiation and pulmonary fibrosis by preventing mitochondrial DNA damage. *Am J Physiol Lung Cell Mol Physiol* 312(1):L68–L78. <https://doi.org/10.1152/ajplung.00188.2016>

18. Kim SJ, Cheresh P, Eren M, Jablonski RP, Yeldandi A, Ridge KM et al (2017) Klotho, an antiaging molecule, attenuates oxidant-induced alveolar epithelial cell mtDNA damage and apoptosis. *Am J Physiol Lung Cell Mol Physiol* 313(1):L16–L26
19. Wu H, Yu Y, Huang H, Hu Y, Fu S, Wang Z et al (2020) Progressive pulmonary fibrosis is caused by elevated mechanical tension on alveolar stem cells. *Cell* 180(1):107. <https://doi.org/10.1016/j.cell.2019.11.027>
20. Kobayashi Y, Tata A, Konkimalla A, Katsura H, Lee RF, Ou J et al (2020) Persistence of a regeneration-associated, transitional alveolar epithelial cell state in pulmonary fibrosis. *Nat Cell Biol* 22(8):934–946. <https://doi.org/10.1038/s41556-020-0542-8>
21. Duerr J, Leitz DHW, Szczygiel M, Dvornikov D, Fraumann SG, Kreuz C et al (2020) Conditional deletion of Nedd4-2 in lung epithelial cells causes progressive pulmonary fibrosis in adult mice. *Nat Commun* 11(1):2012. <https://doi.org/10.1038/s41467-020-15743-6>
22. Guan S, Liu H, Zhou J, Zhang Q, Bi H (2022) The MIR100HG/miR-29a-3p/Tab1 axis modulates TGF-beta1-induced fibrotic changes in type II alveolar epithelial cells BLM-caused lung fibrogenesis in mice. *Toxicol Lett*. <https://doi.org/10.1016/j.toxlet.2022.04.003>
23. Ciechomska M, O'Reilly S, Suwara M, Bogunia-Kubik K, van Laar JM (2014) MiR-29a reduces TIMP-1 production by dermal fibroblasts via targeting TGF-beta activated kinase 1 binding protein 1, implications for systemic sclerosis. *PLoS ONE* 9(12):e115596. <https://doi.org/10.1371/journal.pone.0115596>
24. Yao L, Conforti F, Hill C, Bell J, Drawater L, Li J et al (2019) Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. *Cell Death Differ* 26(5):943–957. <https://doi.org/10.1038/s41418-018-0175-7>
25. Gokey JJ, Snowball J, Green J, Waltamath M, Spinney JJ, Black KE et al (2021) Pretreatment of aged mice with retinoic acid supports alveolar regeneration via upregulation of reciprocal PDGFA signalling. *Thorax* 76(5):456–467
26. Wilson C, Mertens TC, Shivshankar P, Bi W, Collum SD, Wareing N et al (2022) *Sine oculis homeobox homolog 1* plays a critical role in pulmonary fibrosis. *JCI Insight*. <https://doi.org/10.1172/jci.insight.142984>
27. Tian Y, Lv J, Su Z, Wu T, Li X, Hu X et al (2021) LRRK2 plays essential roles in maintaining lung homeostasis and preventing the development of pulmonary fibrosis. *Proc Natl Acad Sci USA*. <https://doi.org/10.1073/pnas.2106685118>
28. Young LR, Gulleman PM, Short CW, Tanjore H, Sherrill T, Qi A et al (2016) Epithelial–macrophage interactions determine pulmonary fibrosis susceptibility in Hermansky–Pudlak syndrome. *JCI Insight* 1(17):e88947. <https://doi.org/10.1172/jci.insight.88947>
29. Hou J, Ji J, Chen X, Cao H, Tan Y, Cui Y et al (2021) Alveolar epithelial cell-derived Sonic hedgehog promotes pulmonary fibrosis through OPN-dependent alternative macrophage activation. *FEBS J* 288(11):3530–3546. <https://doi.org/10.1111/febs.15669>
30. Gu L, Surolia R, Larson-Casey JL, He C, Davis D, Kang J et al (2022) Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling. *Cell Death Differ* 29(1):118–132. <https://doi.org/10.1038/s41418-021-00840-w>
31. Armanios M (2013) Telomeres and age-related disease: how telomere biology informs clinical paradigms. *J Clin Invest* 123(3):996–1002. <https://doi.org/10.1172/JCI66370>
32. van Batenburg AA, Kazemier KM, van Oosterhout MFM, van der Vis JJ, Grutters JC, Goldschmeding R et al (2021) Telomere shortening and DNA damage in culprit cells of different types of progressive fibrosing interstitial lung disease. *ERJ Open Res*. <https://doi.org/10.1183/23120541.00691-2020>
33. Barkauskas CE, Cronce MJ, Rackley CR, Bowie EJ, Keene DR, Stripp BR et al (2013) Type 2 alveolar cells are stem cells in adult lung. *J Clin Invest* 123(7):3025–3036. <https://doi.org/10.1172/JCI68782>
34. Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A et al (2010) Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. *Am J Respir Crit Care Med* 181(3):254–263. <https://doi.org/10.1164/rccm.200810-1615OC>
35. Garcia O, Hiatt MJ, Lundin A, Lee J, Reddy R, Navarro S et al (2016) Targeted type 2 alveolar cell depletion. A dynamic functional model for lung injury repair. *Am J Respir Cell Mol Biol* 54(3):319–330. <https://doi.org/10.1165/rcmb.2014-0246OC>
36. Pfaffenbach KT, Lee AS (2011) The critical role of GRP78 in physiologic and pathologic stress. *Curr Opin Cell Biol* 23(2):150–156
37. Lawson WE, Cheng DS, Degryse AL, Tanjore H, Polosukhin VV, Xu XC et al (2011) Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. *Proc Natl Acad Sci USA* 108(26):10562–10567. <https://doi.org/10.1073/pnas.1107559108>
38. Katzen J, Wagner BD, Venosa A, Kopp M, Tomer Y, Russo SJ et al (2019) An SFTPC BRICHOS mutant links epithelial ER stress and spontaneous lung fibrosis. *JCI Insight*. <https://doi.org/10.1172/jci.insight.126125>
39. Kim SJ, Cheresh P, Jablonski RP, Rachek L, Yeldandi A, Piseaux-Aillon R et al (2020) Mitochondrial 8-oxoguanine DNA glycosylase mitigates alveolar epithelial cell PINK1 deficiency, mitochondrial DNA damage, apoptosis, and lung fibrosis. *Am J Physiol Lung Cell Mol Physiol* 318(5):L1084–L1096
40. Simmen T, Aslan JE, Blagoveshchenskaya AD, Thomas L, Wan L, Xiang Y et al (2005) PACS-2 controls endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis. *EMBO J* 24(4):717–729. <https://doi.org/10.1038/sj.emboj.7600559>
41. Weng H, Ma Y, Chen L, Cai G, Chen Z, Zhang S et al (2020) A new vision of mitochondrial unfolded protein response to the sirtuin family. *Curr Neuropharmacol* 18(7):613–623. <https://doi.org/10.2174/1570159X18666200123165002>
42. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. *Nature* 390(6655):45–51
43. Mencke R, Hillebrands JL (2017) The role of the anti-ageing protein Klotho in vascular physiology and pathophysiology. *Ageing Res Rev* 35:124–146. <https://doi.org/10.1016/j.arr.2016.09.001>
44. Chen G, Liu Y, Goetz R, Fu L, Jayaraman S, Hu MC et al (2018) alpha-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. *Nature* 553(7689):461–466
45. Erben RG (2018) alpha-Klotho's effects on mineral homeostasis are fibroblast growth factor-23 dependent. *Curr Opin Nephrol Hypertens* 27(4):229–235
46. Shaghghi H, Para R, Tran C, Roman J, Ojeda-Lassalle Y, Sun J et al (2021) Glutamine restores mitochondrial respiration in bleomycin-injured epithelial cells. *Free Radic Biol Med* 176:335–344. <https://doi.org/10.1016/j.freeradbiomed.2021.10.006>
47. Wang S, Li X, Ma Q, Wang Q, Wu J, Yu H et al (2022) Glutamine metabolism is required for alveolar regeneration during lung injury. *Biomolecules*. <https://doi.org/10.3390/biom12050728>
48. Yoo HC, Yu YC, Sung Y, Han JM (2020) Glutamine reliance in cell metabolism. *Exp Mol Med* 52(9):1496–1516. <https://doi.org/10.1038/s12276-020-00504-8>
49. Tran TQ, Lowman XH, Kong M (2017) Molecular pathways: metabolic control of histone methylation and gene expression in cancer. *Clin Cancer Res* 23(15):4004–4009. <https://doi.org/10.1158/1078-0432.CCR-16-2506>
50. Adams TS, Schupp JC, Poli S, Ayaub EA, Neumark N, Ahangari F et al (2020) Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. *Sci Adv* 6(28):eaba1983. <https://doi.org/10.1126/sciadv.aba1983>

51. Kathiriya JJ, Wang C, Zhou M, Brumwell A, Cassandras M, Le Saux CJ et al (2022) Human alveolar type 2 epithelium transdifferentiates into metaplastic KRT5(+) basal cells. *Nat Cell Biol* 24(1):10–23. <https://doi.org/10.1038/s41556-021-00809-4>
52. Strunz M, Simon LM, Ansari M, Kathiriya JJ, Angelidis I, Mayr CH et al (2020) Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis. *Nat Commun* 11(1):3559. <https://doi.org/10.1038/s41467-020-17358-3>
53. Wang Y, Liu J, Chen J, Feng T, Guo Q (2015) MiR-29 mediates TGFbeta 1-induced extracellular matrix synthesis through activation of Wnt/beta-catenin pathway in human pulmonary fibroblasts. *Technol Health Care* 23(Suppl 1):S119–S125. <https://doi.org/10.3233/thc-150943>
54. Yao L, Zhou Y, Li J, Wickens L, Conforti F, Rattu A et al (2021) Bidirectional epithelial–mesenchymal crosstalk provides self-sustaining profibrotic signals in pulmonary fibrosis. *J Biol Chem* 297(3):101096. <https://doi.org/10.1016/j.jbc.2021.101096>
55. El-Hashash AH, Al Alam D, Turcatel G, Rogers O, Li X, Bellusci S et al (2011) Six1 transcription factor is critical for coordination of epithelial, mesenchymal and vascular morphogenesis in the mammalian lung. *Dev Biol* 353(2):242–258. <https://doi.org/10.1016/j.ydbio.2011.02.031>
56. Naikawadi RP, Disayabutr S, Mallavia B, Donne ML, Green G, La JL et al (2016) Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis. *JCI Insight* 1(14):e86704. <https://doi.org/10.1172/jci.insight.86704>
57. Gunther S, Fagone P, Jalce G, Atanasov AG, Guignabert C, Nicoletti F (2019) Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets. *Drug Discov Today* 24(2):428–439. <https://doi.org/10.1016/j.drudis.2018.11.003>
58. Gunther S, Bordenave J, Hua-Huy T, Nicco C, Cumont A, Thuillet R et al (2018) Macrophage migration inhibitory factor (MIF) inhibition in a murine model of bleomycin-induced pulmonary fibrosis. *Int J Mol Sci*. <https://doi.org/10.3390/ijms19124105>
59. Aumiller V, Balsara N, Wilhelm J, Günther A, Königshoff M (2013) WNT/β-catenin signaling induces IL-1β expression by alveolar epithelial cells in pulmonary fibrosis. *Am J Respir Cell Mol Biol* 49(1):96–104. <https://doi.org/10.1165/rcmb.2012-0524OC>
60. Baran CP, Opalek JM, McMaken S, Newland CA, O'Brien JM Jr, Hunter MG et al (2007) Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. *Am J Respir Crit Care Med* 176(1):78–89. <https://doi.org/10.1164/rccm.200609-1279OC>
61. Justice JN, Nambiar AM, Tchkonja T, LeBrasseur NK, Pascual R, Hashmi SK et al (2019) Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. *EBioMedicine* 40:554–563. <https://doi.org/10.1016/j.ebiom.2018.12.052>
62. Dahl TB, Holm S, Aukrust P, Halvorsen B (2012) Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. *Annu Rev Nutr* 32:229–243. <https://doi.org/10.1146/annurev-nutr-071811-150746>
63. Lai X, Huang S, Lin S, Pu L, Wang Y, Lin Y et al (2022) Mesenchymal stromal cells attenuate alveolar type 2 cells senescence through regulating NAMPT-mediated NAD metabolism. *Stem Cell Res Ther* 13(1):12. <https://doi.org/10.1186/s13287-021-02688-w>
64. Averyanov A, Koroleva I, Konoplyannikov M, Revkova V, Lesnyak V, Kalsin V et al (2020) First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. *Stem Cells Transl Med* 9(1):6–16. <https://doi.org/10.1002/sctm.19-0037>
65. Takao S, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K et al (2021) Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis. *Stem Cell Res Ther* 12(1):506. <https://doi.org/10.1186/s13287-021-02574-5>
66. Xie T, Kulur V, Liu N, Deng N, Wang Y, Rowan SC et al (2021) Mesenchymal growth hormone receptor deficiency leads to failure of alveolar progenitor cell function and severe pulmonary fibrosis. *Sci Adv*. <https://doi.org/10.1126/sciadv.abg6005>
67. Tanaka Y, Ishitsuka Y, Hayasaka M, Yamada Y, Miyata K, Endo M et al (2015) The exacerbating roles of CCAAT/enhancer-binding protein homologous protein (CHOP) in the development of bleomycin-induced pulmonary fibrosis and the preventive effects of tauroursodeoxycholic acid (TUDCA) against pulmonary fibrosis in mice. *Pharmacol Res* 99:52–62. <https://doi.org/10.1016/j.phrs.2015.05.004>
68. Winters CJ, Koval O, Murthy S, Allamargot C, Sebag SC, Paschke JD et al (2016) CaMKII inhibition in type II pneumocytes protects from bleomycin-induced pulmonary fibrosis by preventing Ca²⁺-dependent apoptosis. *Am J Physiol Lung Cell Mol Physiol* 310(1):L86–94. <https://doi.org/10.1152/ajplung.00132.2015>
69. Yu G, Tzouveleki A, Wang R, Herazo-Maya JD, Ibarra GH, Srivastava A et al (2018) Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. *Nat Med* 24(1):39. <https://doi.org/10.1038/nm.4447>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.